Evidence map›Paper›PMID 38193304›Full record

ReviewHuman vaccines & immunotherapeutics2024

DNA and protein-generated chimeric molecules for delivery of influenza viral epitopes in mouse and humanized NSG transfer models.

Nikolina M Mihaylova, Iliyan K Manoylov, Maria H Nikolova, Jozsef Prechl, Andrey I Tchorbanov

Open access · goldAbstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Nikolina M MihaylovaLaboratory of Experimental Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Iliyan K ManoylovLaboratory of Experimental Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Maria H NikolovaNational Reference Laboratory of Immunology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
Jozsef PrechlR&D Laboratory, Diagnosticum zrt, Budapest, Hungary.
Andrey I TchorbanovLaboratory of Experimental Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.ORCID 0000-0002-9161-3325
Bulgarian Academy of Sciences · BGNational Center of Infectious and Parasitic Diseases · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purified subunit viral antigens are weakly immunogenic and stimulate only the antibody but not the T cell-mediated immune response. An alternative approach to inducing protective immunity with small viral peptides may be the targeting of viral epitopes to immunocompetent cells by DNA and protein-engineered vaccines. This review will focus on DNA and protein-generated chimeric molecules carrying engineered fragments specific for activating cell surface co-receptors for inducing protective antiviral immunity. Adjuvanted protein-based vaccine or DNA constructs encoding simultaneously

Indexed as

Influenza, HumanInfluenza VaccinesOrthomyxoviridaeAnimalsDNAEpitopes, B-LymphocyteHumansMiceDNAEpitopes, B-LymphocyteInfluenza Vaccineschimeric moleculesDNA vaccinesengineered antibodiesinfluenza virus

Identifiers

PMID38193304
PMCPMC10793685
OpenAlexW4390706939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.